Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01435122 · ClinicalTrials.gov registry record · Phase 2
A Study of Axitinib in Advanced Carcinoid Tumors
A Phase 2 study of Carcinoid Tumor, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT01435122 is a Phase 2 study of Carcinoid Tumor that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 30 participants, below the 95-participant average among 8 other Carcinoid Tumor trials with a reported enrollment target (68% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01435122, a Phase 2 study of Carcinoid Tumor, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
The main purpose of this study is to see whether Axitinib will help prolong the time that the patient's carcinoid tumors remain stable, and to examine their treatment response through testing. Researchers also want to find out if Axitinib is safe and tolerable.
Conditions Studied
Interventions
- DRUG Axitinib
Study Locations (2)
California
- University of California San Francisco (UCSF) - San Francisco
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-10-25 |
| Est. Completion | 2018-02-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01435122
The ClinicalTrials.gov registry entry for NCT01435122 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 95-participant average among 8 other Carcinoid Tumor trials with a reported enrollment target (68% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Axitinib is the first listed.
NCT01435122 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Florida.
Frequently Asked Questions
What is clinical trial NCT01435122 about?
NCT01435122 is a clinical study titled "A Study of Axitinib in Advanced Carcinoid Tumors". The main purpose of this study is to see whether Axitinib will help prolong the time that the patient's carcinoid tumors remain stable, and to examine their treatment response through testing. Researchers also want to find out if Axitinib is safe and tolerable.
What is the current status of trial NCT01435122?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2011-10-25. Estimated completion is 2018-02-13.
What conditions does trial NCT01435122 study?
This clinical trial studies the following conditions: Carcinoid Tumor.
What interventions are being tested in trial NCT01435122?
The interventions under investigation include: Axitinib (DRUG).
Who is sponsoring clinical trial NCT01435122?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01435122 being conducted?
This trial has 2 study locations across California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
RECRUITING · Phase 2
-
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
COMPLETED · Phase 2
-
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
COMPLETED · Phase 2
-
Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
COMPLETED · Phase 2
-
A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors
COMPLETED · Phase 2
-
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.